Crinetics Pharmaceuticals, Inc. (CRNX)
84.95
0.00 (0.00%)
Inactive · Last trade price on Aug 31, 2026
Crinetics Pharmaceuticals Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -501.61 | -465.32 | -298.41 | -214.53 | -163.92 | -107.64 |
Depreciation & Amortization | 4.24 | 3.89 | 2.79 | 1.1 | 0.98 | 0.92 |
Loss (Gain) From Sale of Assets | 0.03 | 0.05 | 0.05 | 0.01 | - | - |
Loss (Gain) From Sale of Investments | -10.58 | -15.43 | -14.93 | -6.27 | 0.03 | 0.42 |
Loss (Gain) on Equity Investments | - | - | 0.47 | 5.2 | 1.01 | - |
Stock-Based Compensation | 98.98 | 91.02 | 69.39 | 40.94 | 28.27 | 17.35 |
Other Operating Activities | 2.8 | 3.01 | 3.04 | -0.79 | -0.19 | -0.74 |
Change in Accounts Receivable | -11.96 | -0.59 | - | - | - | - |
Change in Inventory | -3.29 | -2.02 | - | - | - | - |
Change in Accounts Payable | 15.05 | 28.98 | 13.32 | 12.36 | 10.99 | 6.29 |
Change in Unearned Revenue | -0.76 | -1.84 | 0.07 | -1.54 | 8.34 | - |
Change in Other Net Operating Assets | -15.42 | -19.69 | -5.98 | -5.07 | -0.72 | -5.2 |
Operating Cash Flow | -422.52 | -377.92 | -230.19 | -168.6 | -115.21 | -88.59 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | -2.66 | -5.76 | -3.84 | -4.69 | -1.66 | -0.44 |
Investment in Securities | -1.49 | 179.67 | -570.97 | -195.73 | -172.32 | -56.05 |
Investing Cash Flow | -4.15 | 173.91 | -574.82 | -200.41 | -173.98 | -56.48 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Issuance of Common Stock | 428.5 | 40.61 | 1,030 | 391.78 | 129.72 | 265.64 |
Other Financing Activities | -0.58 | - | -14.98 | -0.54 | -7.76 | -12.96 |
Financing Cash Flow | 427.92 | 40.61 | 1,015 | 391.24 | 121.96 | 252.68 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Foreign Exchange Rate Adjustments | 0.02 | -0.11 | - | - | - | - |
Net Cash Flow | 1.27 | -163.51 | 209.65 | 22.22 | -167.22 | 107.61 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -425.18 | -383.68 | -234.04 | -173.29 | -116.86 | -89.02 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Margin | -1008.58% | -4985.50% | -22525.31% | -4318.12% | -2466.98% | -8258.26% |
Free Cash Flow Per Share | -4.26 | -4.08 | -2.90 | -2.98 | -2.25 | -2.32 |
Levered Free Cash Flow | -248.76 | -206.91 | -136.41 | -93.53 | -62.51 | -48.47 |
Unlevered Free Cash Flow | -248.76 | -206.91 | -136.41 | -93.53 | -62.51 | -48.47 |